UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
Location status: Recruiting
Location contact
Daniel Pieratt, MPA
CONTACT
Morgan L Paul, BSN
CONTACT
Rakesh Sindhi, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT03959800
The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
Interested in participating?
Request Info0 year–99 year
All sexes
Observational
Pittsburgh, Pennsylvania, 15224, United States
Location status: Recruiting
Daniel Pieratt, MPA
CONTACT
Morgan L Paul, BSN
CONTACT
Rakesh Sindhi, MD
PRINCIPAL_INVESTIGATOR
Pediatric liver cancers are rare, affecting at times no more than 1 in one million population. Understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. Current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. Such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. Nor does such a classification system explain why two different classes of cancers behave the same way. Understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
To achieve these goals, large numbers of such cancer patients or affected tissue must be collected. This is not possible in any single institution, or any single country. The current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. These biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. The results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Recurrence free survival at 2 years
DNA sequence variants
Time frame: Recurrence free survival at 2 years
Differentially expressed genes
Time frame: Duration of active chemotherapy to two years after surgical treatment
chromatin accessibility
Time frame: Duration of active chemotherapy to two years after surgical treatment
Differential methylation
Time frame: Duration of active chemotherapy to two years after surgical treatment
differentially enriched immune cells
Time frame: Duration of active chemotherapy to two years after surgical treatment
Survival
Time frame: Duration of active chemotherapy to two years after surgical treatment
Relapse
Contact information is provided by the study sponsor or research team.
Daniel Pieratt, MPA
CONTACT
Morgan Paul, BSN
CONTACT
University of Pittsburgh
Other
Genetic and Molecular Basis of Pediatric Liver Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00019630
Adenocarcinoma, Astrocytoma
Bethesda, Maryland, United States
View Trial DetailsNCT07148050
Adenocarcinoma, Carcinoma
Seattle, Washington, United States
View Trial DetailsNCT06198296
Adenocarcinoma, Carcinoma
Houston, Texas, United States
View Trial DetailsNCT02867592
Adenocarcinoma, Adrenal Cortex Diseases
Birmingham, Alabama, United States
View Trial Details